Mereo BioPharma Group Balance Sheet Health
Financial Health criteria checks 6/6
Mereo BioPharma Group has a total shareholder equity of $72.5M and total debt of $5.6M, which brings its debt-to-equity ratio to 7.7%. Its total assets and total liabilities are $88.7M and $16.2M respectively.
Key information
7.7%
Debt to equity ratio
US$5.55m
Debt
| Interest coverage ratio | n/a |
| Cash | US$80.52m |
| Equity | US$72.54m |
| Total liabilities | US$16.21m |
| Total assets | US$88.75m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MAH0's short term assets ($86.7M) exceed its short term liabilities ($14.2M).
Long Term Liabilities: MAH0's short term assets ($86.7M) exceed its long term liabilities ($2.0M).
Debt to Equity History and Analysis
Debt Level: MAH0 has more cash than its total debt.
Reducing Debt: MAH0's debt to equity ratio has reduced from 51% to 7.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MAH0 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MAH0 has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 7.5% each year.